Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Recruiting · NCT06593314 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Texas Southwestern Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
Message with EchoGoStandard Message
What this trial is about
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Eligibility criteria (as published)
Clinical cohort inclusion exclusion criteria:
Inclusion Criteria:
* Patients with diagnosis of Type 2 diabetes and High WATCH DM score.
* Echocardiogram available in last 6-months.
Exclusion Criteria:
* History of HF
* Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA
Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Where it is running
2 locations listed across 1 US state.
- UT Southwestern Medical Center - Dallas, Texas, United States
- UT Southwestern Medical Center - Dallas, Texas, United States